Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CCKBR | P32239 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29334350 | 0.92 | KRAS (0.40) | KRASHCRTR2 | |
| SCHEMBL30855210 | 0.92 | KRAS (0.40) | KRASHCRTR2 | |
| SCHEMBL29334243 | 0.87 | KRAS (0.34) | KRAS | |
| SCHEMBL29333403 | 0.86 | SLC6A7 (0.34) | KRASGSK3BCCKBR | |
| SCHEMBL29334349 | 0.85 | KRAS (0.30) | KRAS | |
| SCHEMBL31008574 | 0.83 | JAK3 (0.31) | — | |
| SCHEMBL29333558 | 0.83 | JAK3 (0.31) | — | |
| SCHEMBL29333408 | 0.82 | PIK3C3 (0.33) | GSK3B | |
| SCHEMBL31008645 | 0.82 | JAK2 (0.33) | KRAS | |
| SCHEMBL29333564 | 0.82 | MTOR (0.37) | GSK3BCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | KRAS 531/4885HCRTR2 3315/4885GSK3B 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.